The news of Baird maintaining an Outperform rating on Phreesia indicates a positive outlook for the company. However, the lowering of the price target from $41 to $40 may create some uncertainty among investors. The overall impact on the stock price is expected to be neutral in the short term as the positive rating is balanced by the slightly reduced price target.